Chinese english Germany Japanese Korea

Encorafenib (LGX818)

Encorafenib (LGX818) Struktur
1269440-17-6
CAS-Nr.
1269440-17-6
Englisch Name:
Encorafenib (LGX818)
Synonyma:
Encorafenib;LGX818;LGX-818;LGX 818;CS-1037;NSC4820;NSC 4820;NSC-4820;LGX818, >=98%;LGX818, Encorafenib
CBNumber:
CB42668617
Summenformel:
C22H27ClFN7O4S
Molgewicht:
540.01
MOL-Datei:
1269440-17-6.mol
Request For Quotation

Encorafenib (LGX818) Eigenschaften

Schmelzpunkt:
184-185°C
Dichte
1.45±0.1 g/cm3(Predicted)
storage temp. 
-20°C Freezer, Under inert atmosphere
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
pka
5.94±0.10(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Encorafenib (LGX818) Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials. However, the underlying mechanism remains to be elucidated. Here we show that LGX818 potently decreased ERK phosphorylation and inhibited proliferation in BRAFV600E melanoma cell lines. Moreover, LGX818 downregulated CyclinD1 in a glycogen synthase kinase 3β-independent manner and induced cell cycle arrest in the G1 phase.

Verwenden

LGX 818 is potent and selective BRAFV600E kinase inhibitor and can be used for the treatment of proliferative diseases such as solid tumor diseases.

Trademarks

Braftovi

Biologische Aktivität

Encorafenib (LGX818) is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.

Clinical Use

Encorafenib (LGX818) is a new-generation BRAF inhibitor. It is currently under investigation in clinical trials for the treatment of BRAF mutant metastatic melanoma patients . LGX818 induces sustained mitogen-activated protein kinase (MAPK) pathway inhibition and has selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E. However, the mechanism by which LGX818 suppresses BRAF mutant melanoma cell proliferation has not been thoroughly investigated.

Encorafenib (LGX818) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

2-((2-benzylidene-1-isopropylhydrazinyl)methylene)malononitrile CarbaMic acid, N-[(1S)-2-[[4-[3-(3-aMino-5-chloro-2-fluorophenyl)-1-(1-Methylethyl)-1H-pyrazol-4-yl]-2-pyriMidinyl]aMino]-1-Methylethyl]-, Methyl ester

Downstream Produkte

Encorafenib (LGX818) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 146)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Rochi Pharmaceutical Co.,Ltd. 		21-38751876 +8615000076078
 info@rochipharma.com China 431 58
Jinan Carbotang Biotech Co.,Ltd. 		+8615866703830
 figo.gao@foxmail.com China 7353 58
Hubei Jusheng Technology Co.,Ltd. 		18871490254
linda@hubeijusheng.com CHINA 28180 58
BOC Sciences 		+1-631-485-4226
inquiry@bocsci.com United States 19553 58
career henan chemical co 		+86-0371-86658258 +8613203830695
 factory@coreychem.com China 29826 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD 		86-571-88216897,88216896 13588875226
 sales@hzclap.com CHINA 6313 58
Dideu Industries Group Limited 		+86-29-89586680 +86-15129568250
 1026@dideu.com China 25502 58
Baoji Guokang Bio-Technology Co., Ltd. 		0917-3909592 13892490616
 gksales1@gk-bio.com China 9322 58
Zhejiang J&C Biological Technology Co.,Limited 		+1-2135480471 +1-2135480471
 sales@sarms4muscle.com China 10522 58
Hangzhou Proserre Chemical Co.,Ltd. 		+86-571-86088112
info@proserre.com China 1077 58
  • LGX 818
  • LGX-818
  • (S)-Methyl [1-[[4-[3-[5-chloro-2-fluoro-3-(methylsulfonamido)phenyl]-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
  • Encorafenib (LGX818)
  • Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester
  • LGX 818 (S)-Methyl [1-[[4-[3-[5-chloro-2-fluoro-3-(methylsulfonamido)phenyl]-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
  • LGX818, >=98%
  • LGX818, Encorafenib
  • CS-1037
  • methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
  • LGX 818; LGX-818;LGX818
  • ENCORAFENIB;LGX818; LGX-818
  • LGX818; LGX-818; LGX 818; ENCORAFENIB.
  • methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
  • Encorafenib (LGX818) USP/EP/BP
  • Methyl N-[(2s)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
  • NSC 4820
  • NSC4820
  • NSC-4820
  • LGX818
  • Encorafenib
  • Cymoxanil Impurity 3
  • 1269440-17-6
  • C22H27ClFN7O4S
  • Inhibitors
Copyright 2019 © ChemicalBook. All rights reserved